In this issue of Px Wire, we take a hard look at a host of major milestones coming up toward ambitious global targets for ending the epidemic. We also include detailed infographics on showing the status of oral PrEP rollout in the countries where trial sites are located, explaining the demographics of Africa’s “youth bulge” and its implications for the global response and more.
Px Wire January-March 2018, Vol. 11, No. 1
Target Tracking for Epidemic Control
Calculating progress toward the UNAIDS Fast Track Goals is complex but ambitious targets are the best kind. AVAC has long argued they propel action even if they aren’t met. But when it comes to achieving epidemic control, progress must be properly calculated, and can never be confused with success.
Appearing in Px Wire, this is a modified version of a graphic appearing in AVAC Report 2017.
Standard of Care in the Era of PrEP
Every research trial of a new HIV prevention option offers a package of services to protect participants from HIV. This standard of care is essential to the design of an ethical trial.
So what do we do now that oral PrEP has hit the world: It works if you take it; roll out is reaching some places and populations better than others. And people on PrEP often need support to stick with it. All this makes adding Oral PrEP a paramount question for trials. This month’s Px Pulse follows a recent summit in Cape Town South Africa where advocates, researchers and regulators confronted the high stakes of post-PrEP prevention research.
What’s the State of the Field? AVAC Report 2017
On the eve of World AIDS Day 2017, AVAC published its annual report on the state of the field. AVAC Report 2017: Mixed Messages and How to Untangle Them is a must-read for anyone tracking the progress of HIV prevention around the world. In this month’s episode of Px Pulse, AVAC’s Director of Strategy & Content Emily Bass shares highlights from the report and calls for action on the unfinished work of scaling up prevention.
2018 and HIV Prevention: AVAC’s Take
In this episode hear about recently published findings from a study out of Rakai, Uganda confirm that scaling up of a combination of existing interventions, such as voluntary medical male circumcision and antiretroviral therapy provides protection from HIV at the population-level. How do we apply these findings at the global level? How should advocates prepare for results—anticipated in 2019—of the ECHO trial that’s looking at the effect of hormonal contraceptives on HIV risk? And what needs to happen in 2018 to reach long-term global targets for ending the epidemic?
Video Series: Lessons from the Field
Six short videos spotlight lessons learned at PrEP demonstration projects run by LVCT Health in Kenya. The series explores key issues from the introduction of PrEP and managing symptoms to adherence and the role of support groups.
NIH-Funded HIV Trial Networks: A family tree
This graphic provides a visual history of the DAIDS Networks and a look at what’s proposed for the next funding cycle. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
The Delivery Challenge
This figure shows the timeline to achieve public health targets related to a new intervention, both globally and (in dashed lines) in the US. The message: it takes time and, based on history, today’s prevention tools are on track. It appears in AVAC Report 2017: Mixed messages and how to untangle them.
Total Global HIV Prevention R&D Investment by Prevention Option, 2015–2016
This graphic shows the percentage of total global investment in HIV prevention spent on different interventions in 2015 and 2016. For much more on HIV prevention research & development funding, visit www.hivresourcetracking.org.
US HIV Research: A family tree
This graphics shows a family tree representing HIV research in the United States. It appears in AVAC Report 2017: Mixed messages and how to untangle them.